Entity

Time filter

Source Type

St. Louis, MO, United States

Ong F.S.,Illumina | Lin J.C.,Rare Genomics Institute | Grosu D.S.,Illumina | Fan J.-B.,Illumina
Genomics | Year: 2013

The development of next-generation sequencing (NGS) technology has made DNA sequencing not only rapid and cost-effective, but also highly accurate and reproducible. The translational utility of genomic sequencing is clear, from understanding of human genetic variation and its association with disease risk and individual response to treatment, to the interpretation and translation of the data for clinical decision making. It will be a critical technology for disease characterization and monitoring in molecular pathology and is expected to become a central piece of routine healthcare management which will result in accurate and reliable reporting, a prerequisite for physicians to practice genomic medicine. © 2013 Elsevier Inc. Source


Fumagalli D.C.,Rare Genomics Institute | Gouw A.M.,Rare Genomics Institute | Gouw A.M.,Stanford University
Yale Journal of Biology and Medicine | Year: 2015

Given the current funding situation of the National Institutes of Health, getting funding for rare disease research is extremely difficult. In light of the enormous potential for research in the rare diseases and the scarcity of research funding, we provide a case study of a novel successful crowdfunding approach at a non-profit organization called Rare Genomics Institute. We partner with biotechnology companies willing to donate their products, such as mouse models, gene editing software, and sequencing services, for which researchers can apply. First, we find that personal stories can be powerful tools to seek funding from sympathetic donors who do not have the same rational considerations of impact and profit. Second, for foundations facing funding restrictions, company donations can be a valuable tool in addition to crowdfunding. Third, rare disease research is particularly rewarding for scientists as they proceed to be pioneers in the field during their academic careers. Overall, by connecting donors, foundations, researchers, and patients, crowdfunding has become a powerful alternative funding mechanism for personalized medicine. © 2015. Source


Rajasimha H.K.,Organization for Rare Diseases India | Shirol P.B.,Organization for Rare Diseases India | Ramamoorthy P.,Organization for Rare Diseases India | Hegde M.,Organization for Rare Diseases India | And 15 more authors.
Genetics research | Year: 2014

In order to address the unmet needs and create opportunities that benefit patients with rare disease in India, a group of volunteers created a not-for-profit organization named Organization for Rare Diseases India (ORDI; www.ordindia.org). ORDI plans to represent the collective voice and advocate the needs of patients with rare diseases and other stakeholders in India. The ORDI team members come from diverse backgrounds such as genetics, molecular diagnostics, drug development, bioinformatics, communications, information technology, patient advocacy and public service. ORDI builds on the lessons learned from numerous similar organizations in the USA, European Union and disease-specific rare disease foundations in India. In this review, we provide a background on the landscape of rare diseases and the organizations that are active in this area globally and in India. We discuss the unique challenges in tackling rare diseases in India, and highlight the unmet needs of the key stakeholders of rare diseases. Finally, we define the vision, mission, goals and objectives of ORDI, identify the key developments in the health care context in India and welcome community feedback and comments on our approach. Source


Sager M.,Washington University in St. Louis | Sager M.,Rare Genomics Institute | Yeat N.C.,Rare Genomics Institute | Yeat N.C.,Washington University in St. Louis | And 7 more authors.
Expert Review of Molecular Diagnostics | Year: 2015

Transcriptomic technologies are evolving to diagnose cancer earlier and more accurately to provide greater predictive and prognostic utility to oncologists and patients. Digital techniques such as RNA sequencing are replacing still-imaging techniques to provide more detailed analysis of the transcriptome and aberrant expression that causes oncogenesis, while companion diagnostics are developing to determine the likely effectiveness of targeted treatments. This article examines recent advancements in molecular profiling research and technology as applied to cancer diagnosis, clinical applications and predictions for the future of personalized medicine in oncology. © 2015 Taylor & Francis. Source


Dolled-Filhart M.P.,Rare Genomics Institute | Lordemann A.,Rare Genomics Institute | Lordemann A.,Genome Technology Access Center | Dahl W.,Rare Genomics Institute | And 7 more authors.
Personalized Medicine | Year: 2012

A decade after the complete sequencing of the human genome, combined with recent advances in throughput and sequencing costs, the genetics of rare diseases has entered a new era. There has now been an explosion in the identification and mapping of rare diseases, with over 10,000 exomes having been sequenced to date. This article surveys the progress and development of technologies to understand rare disease; it provides a historical overview of traditional techniques such as karyotyping and homozygosity mapping, reviews current methods of whole-exome and -genome sequencing, and provides a future perspective on upcoming developments such as targeted drugs and gene therapy. This article will discuss the implications of these methods for rare disease research, along with a discussion of the success stories that provide great hope and optimism for patients and scientists alike. © 2012 Future Medicine Ltd. Source

Discover hidden collaborations